Lee, D. (., Rodrigues, K., Rana, M., Kozy, K., Salazar, S., Jensen, A., Desai, M., Mallampet, J., Lohman, C., Huang, Y., Kang, X., Tian, F., Mutter, J., Phillips, N., Schweitzer, C., Cheema, F., Mikkilineni, L., Rezvani, A., Johnston, L., Shizuru, J., Meyer, E., Lowsky, R., Weng, W., Smith, M., Bharadwaj, S., Negrin, R., Sidana, S., Muffly, L., Sahaf, B., Natkunam, Y., Shen, R., Frank, M., Mackall, C., Good, Z., Alizadeh, A., Miklos, D., Dahiya, S. (2025). Double-dose axicabtagene ciloleucel (Axi-Cel-2) as second-line therapy for high-risk relapsed or refractory large B-cell lymphoma (r/rLBCL): Interim results from a Phase 1b study. Blood. https://doi.org/10.1182/blood-2025-671